Literature DB >> 19348968

Substrate-dependent modulation of enzyme activity by allosteric effector antibodies.

John N Barlow1, Katja Conrath, Jan Steyaert.   

Abstract

We investigate the kinetic effects of antibody variable domain fragments derived from heavy chain antibodies (VHH domains) that behave as allosteric effectors of the nucleoside hydrolase from Trypanosoma vivax (TvNH). Strikingly, these antibodies can stimulate or inhibit TvNH steady-state activity, depending on the substrate used. This effect was investigated in greater detail using steady-state and pre-steady-state kinetic experiments. The most potent allosteric effector, VHH 1589, inhibits certain steps on the TvNH catalytic pathway (e.g. N-glycosidic bond cleavage) but increases the rates of others (e.g. substrate and product release). For the natural nucleoside 7-methyl guanosine, where product ribose release is rate determining, the net effect of VHH 1589 binding is to increase k(cat). For the poor substrate pNPR, VHH 1589 causes chemistry (O-glycosidic bond cleavage) to become rate determining and both k(cat)/K(m) and k(cat) to decrease. Thus, the substrate-dependent effects of VHH 1589 binding are caused by differences in the relative rates of chemistry with respect to subsequent steps on the catalytic pathway for these two substrates. We discuss possible mechanisms for these kinetic effects and the implications for allosteric effector drug development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19348968     DOI: 10.1016/j.bbapap.2009.03.019

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  Antibody-enabled small-molecule drug discovery.

Authors:  Alastair D G Lawson
Journal:  Nat Rev Drug Discov       Date:  2012-06-29       Impact factor: 84.694

2.  Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies.

Authors:  Dean P Staus; Laura M Wingler; Ryan T Strachan; Soren G F Rasmussen; Els Pardon; Seungkirl Ahn; Jan Steyaert; Brian K Kobilka; Robert J Lefkowitz
Journal:  Mol Pharmacol       Date:  2013-12-06       Impact factor: 4.436

3.  A nanobody that recognizes a 14-residue peptide epitope in the E2 ubiquitin-conjugating enzyme UBC6e modulates its activity.

Authors:  Jingjing Ling; Ross W Cheloha; Nicholas McCaul; Zhen-Yu J Sun; Gerhard Wagner; Hidde L Ploegh
Journal:  Mol Immunol       Date:  2019-09-10       Impact factor: 4.407

4.  Structural mechanism underpinning Thermus oshimai Pif1-mediated G-quadruplex unfolding.

Authors:  Yang-Xue Dai; Hai-Lei Guo; Na-Nv Liu; Wei-Fei Chen; Xia Ai; Hai-Hong Li; Bo Sun; Xi-Miao Hou; Stephane Rety; Xu-Guang Xi
Journal:  EMBO Rep       Date:  2022-06-23       Impact factor: 9.071

5.  Nanobody-based binding assay for the discovery of potent inhibitors of CFTR inhibitory factor (Cif).

Authors:  Natalia Vasylieva; Seiya Kitamura; Jiexian Dong; Bogdan Barnych; Kelli L Hvorecny; Dean R Madden; Shirley J Gee; Dennis W Wolan; Christophe Morisseau; Bruce D Hammock
Journal:  Anal Chim Acta       Date:  2019-01-09       Impact factor: 6.558

Review 6.  Biotechnological applications of recombinant single-domain antibody fragments.

Authors:  Ario de Marco
Journal:  Microb Cell Fact       Date:  2011-06-09       Impact factor: 5.328

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.